Recent 8-K filings for OMER

• August 12, 2026, 4:09 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Omeros Q2: YARTEMLEA net rev $28.5M (+190% QoQ); adjusted EPS $0.02 vs -$0.24

  YARTEMLEA net revenue $28.5M in Q2 2026 (gross $32.2M), up 190% from Q1 gross $11.1M; gross-to-net ~11.5%.

• July 20, 2026, 5:05 PM ET debt materiality 0.65 neutral item 8.01

  Omeros repurchases $14.5M of convertible notes; total $30.5M retired, $40.3M remains

  Repurchased $14.5M principal of 9.50% Convertible Senior Notes due 2029 for ~$29.0M total (incl. accrued interest).

• May 13, 2026, 4:06 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  Omeros Q1 net income $56.1M on $73.1M non-cash gain; YARTEMLEA net sales $9.9M

  GAAP net income $56.1M ($0.78/share) vs. net loss $33.5M ($0.58) in Q1 2025; includes $73.1M non-cash gain on embedded derivatives.

• March 31, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Omeros posts Q4 net income of $86.5M; YARTEMLEA approved, zaltenibart deal closed

  Q4 2025 net income $86.5M ($1.22/diluted EPS) vs. net loss $31.4M ($0.54) in Q4 2024; full-year net loss narrowed to $3.4M ($0.05) from $156.8M ($2.70).

• December 29, 2025, 6:59 PM ET other material materiality 0.90 positive item 9.01

  FDA approves Omeros' YARTEMLEA as first therapy for TA-TMA; launch set for Jan 2026

  YARTEMLEA (narsoplimab-wuug) approved for adults and children ≥2 years with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

• December 1, 2025, 6:59 PM ET M&A materiality 0.95 positive item 1.02item 2.01item 9.01 ◈ M&A Transactions◈ Material Agreements

  Omeros closes zaltenibart sale to Novo Nordisk for $240M upfront; repays debt, launches $100M buyback

  Closed sale of zaltenibart to Novo Nordisk for $240M upfront; eligible for up to $2.1B in milestones plus tiered royalties on net sales.

• November 13, 2025, 6:59 PM ET other material materiality 0.90 positive item 2.02item 9.01

  Omeros Q3 net loss narrows; Novo Nordisk deal for zaltenibart up to $2.1B

  Q3 net loss $30.9M ($0.47/sh) vs $32.2M ($0.56/sh) a year ago; adjusted net loss $22.1M ($0.34/sh).

• October 15, 2025, 7:59 PM ET M&A materiality 0.95 positive item 1.01item 8.01item 9.01

  Omeros sells global rights to zaltenibart to Novo Nordisk for up to $2.1B

  Upfront $240M cash plus near-term milestones total $340M; up to $2.1B including development & sales milestones plus tiered royalties.

• August 14, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Omeros Q2 net loss narrows to $25.4M; narsoplimab PDUFA extended to Dec 2025; debt reduced by $80M

  Net loss of $25.4M ($0.43/sh) vs $56.0M ($0.97/sh) a year ago; cash, short-term investments $28.7M at June 30.

• July 25, 2025, 7:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  Omeros prices $22M offering, discloses advanced partnership talks, narsoplimab PDUFA now Dec 2025

  Sold 5,365,853 shares at $4.10 each to Polar Asset Management; net proceeds ~$20.3M; expected close July 28.

• May 15, 2025, 7:59 PM ET earnings materiality 0.85 neutral item 1.01item 2.02item 2.03item 3.02item 8.01item 9.01 ◈ Debt Financings

  Omeros Q1 net loss $0.58/sh; swaps $70.8M of 2026 notes for 2029 notes at 9.5%

  Net loss $33.5M ($0.58/diluted) vs $37.2M ($0.63) a year ago; OMIDRIA royalties $6.7M on sales of $22.3M.

• May 6, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Omeros announces FDA accepts BLA resubmission for narsoplimab in TA-TMA; PDUFA late Sept 2025

  FDA accepted Class 2 resubmission of BLA for narsoplimab for TA-TMA; PDUFA target action date late September 2025.

• March 31, 2025, 7:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01

  Omeros Q4 net loss $31.4M; BLA resubmitted for narsoplimab; PDUFA Sept 2025

  Net loss Q4 2024 $31.4M ($0.54/sh) vs Q3 $32.2M; FY2024 loss $156.8M vs $117.8M prior year.

• February 20, 2025, 6:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Omeros reports robust narsoplimab EAP survival data in TA-TMA; BLA resubmission planned Q1 2025

  Combined EAP + pivotal trial vs external control: HR 0.34-0.46, p-values <0.00001 to 0.00002.

• January 16, 2025, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Omeros narsoplimab sensitivity analyses confirm survival benefit; BLA resubmission planned this quarter

  Sensitivity analyses show HR 0.24–0.42 vs external control, p-values 0.0124 to <0.00001, confirming primary endpoint robustness.

• December 19, 2024, 6:59 PM ET other material materiality 0.90 positive item 8.01item 9.01

  Omeros narsoplimab meets TA-TMA pivotal trial primary endpoint; HR 0.32 for survival

  Narsoplimab-treated TA-TMA patients had over 3-fold reduction in risk of death (HR 0.32, 95% CI 0.23-0.44, p<0.00001) vs >100 external control patients.

• November 13, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Omeros Q3 net loss $32.2M; narsoplimab BLA resubmission path cleared after FDA meeting

  Net loss Q3 2024: $32.2M ($0.56/sh) vs $37.8M ($0.60/sh) in Q3 2023; nine-month loss $125.5M.

• August 7, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Omeros Q2 net loss $56M ($0.97/sh) vs $37M; restructures debt with $67M term loan

  Net loss $56.0M ($0.97/sh) vs $37.3M ($0.59); includes $17.6M narsoplimab charge, $21.2M debt repurchase.

• June 3, 2024, 7:59 PM ET debt materiality 0.85 positive item 1.01item 2.03item 7.01item 8.01item 9.01

  Omeros enters $92.1M term loan, repurchases $118.1M convertible notes at 74.75% of par, extinguishes $51M debt

  New $67.1M initial term loan funded June 3, 2024, plus $25M delayed draw available upon FDA approval of narsoplimab for TA-TMA.

• May 15, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Omeros Q1 net loss $37.2M; cash extends into 2026 after $115.5M royalty deal

  Net loss $37.2M ($0.63/share) vs $33.7M ($0.54) in Q1 2023; loss from cont ops $43.9M vs $39.7M.

• April 1, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Omeros posts Q4 net loss $9.1M, secures $115.5M from OMIDRIA royalty sale

  Q4 2023 net loss $9.1M ($0.15/sh) vs Q3 loss $37.8M; full-year net loss $117.8M ($1.88/sh) vs prior-year net income $47.4M.

• February 7, 2024, 6:59 PM ET other material materiality 0.70 neutral item 1.01item 2.03

  Omeros amends royalty deal with DRI, receives $115M for expanded OMIDRIA royalty sale

  Omeros received $115M cash from DRI Healthcare Acquisitions LP for an expanded interest in OMIDRIA royalties.

• November 9, 2023, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  Omeros Q3 net loss $37.8M; discontinues IgA nephropathy trial, targets narsoplimab BLA in mid-2024

  Net loss of $37.8M ($0.60/sh) vs $17.5M prior year; continuing ops loss $51.7M, down from $54.8M.

• October 16, 2023, 7:59 PM ET other material materiality 0.85 negative item 8.01item 9.01

  Omeros Phase 3 ARTEMIS-IGAN trial fails primary endpoint; narsoplimab BLA in IgAN discontinued

  Narsoplimab did not achieve statistically significant reduction in proteinuria at 36 weeks vs placebo (24-hour UPE >2 g/day).

• August 9, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  Omeros Q2 2023 net loss $37.3M ($0.59/share); cash $341M; narsoplimab BLA path set

  Net loss Q2 2023 $37.3M vs $30.8M prior year; six-month loss $71.0M; cash burn $30.1M.

• May 9, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Omeros Q1 net loss $33.7M; receives $200M milestone; OMS906 data positive in PNH

  Net loss $33.7M ($0.54 per share) vs $33.0M ($0.53) Q1 2022; cash burn $23.6M excl $200M milestone.

• March 13, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Omeros Q4 net income $128.7M on $200M milestone; OMIDRIA royalties record $35.8M sales

  Q4 net loss from continuing ops $46.0M ($0.73/share) vs $54.8M loss in Q3; cash burn $26M.

• February 6, 2023, 6:59 PM ET other material materiality 0.75 positive item 2.02item 8.01item 9.01 ◈ Earnings Releases

  Omeros receives $200M milestone payment from Rayner; 2022 OMIDRIA sales $131M

  Rayner paid $200M milestone plus accrued interest on Feb 3, 2023; U.S. royalty rate drops from 50% to 30%.

• November 9, 2022, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  Omeros reports Q3 2022 net loss $17.5M; FDA denies narsoplimab appeal, provides resubmission path

  Net loss $17.5M ($0.28/share) vs $22.7M loss in 3Q21; cash and equivalents $221M at Sept 30.

• October 6, 2022, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 2.03

  Omeros sells portion of OMIDRIA royalties for $125M; total capped payments of $188.4M through 2030

  Received $125M upfront from DRI Healthcare for partial sale of OMIDRIA royalties.

• August 9, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Omeros reports Q2 2022 net loss $30.9M; narsoplimab FDA dispute decision expected August

  Royalties of $17.2M on OMIDRIA sales of $34.5M, a new all-time high.

• May 10, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Omeros Q1 net loss $33.0M ($0.53/shr); OMIDRIA royalties $13.8M; preparing FDA dispute resolution

  Net loss of $33.0M ($0.53/shr) vs $35.1M ($0.57) in Q1 2021; non-cash items $4.2M.

• March 1, 2022, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Omeros Q4 net income $280.6M including OMIDRIA gain; adjusted loss $0.37/share

  Net income Q4 2021 $280.6M ($4.48/share) includes $184.6M non-cash gain from OMIDRIA royalty capitalization and $126M cash proceeds from sale.

• December 30, 2021, 6:59 PM ET M&A materiality 0.90 positive item 2.01item 8.01item 9.01

  Omeros closes $126M OMIDRIA sale to Rayner; deal valued >$1B including royalties

  Received ~$126M cash at closing; retains accounts receivable.

• December 2, 2021, 6:59 PM ET M&A materiality 0.90 positive item 1.01item 8.01item 9.01

  Omeros sells OMIDRIA franchise to Rayner Surgical for $125M upfront plus milestones and royalties

  Upfront payment of $125M at closing; potential $200M milestone if separate payment secured for four continuous years.

• November 9, 2021, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Omeros Q3 OMIDRIA rev $30M (+4.1% QoQ); net loss narrows; FDA CRL for narsoplimab

  OMIDRIA revenue $30.0M in Q3, up 4.1% from Q2 $28.8M; driven by ASC growth.

• October 18, 2021, 7:59 PM ET regulatory materiality 0.90 negative item 5.02item 7.01item 8.01item 9.01 ◈ executive_change

  Omeros receives FDA Complete Response Letter for narsoplimab BLA; director Ray Aspiri retires

  Ray Aspiri retired from Omeros board effective Oct 14, 2021, with no disagreement with the company.

• October 1, 2021, 7:59 PM ET regulatory materiality 0.90 negative item 8.01item 9.01

  Omeros receives FDA deficiency notice for narsoplimab BLA; PDUFA date expected to be missed

  FDA identified deficiencies in narsoplimab BLA for HSCT-TMA, precluding labeling/post-marketing discussions.

• August 9, 2021, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Omeros Q2 OMIDRIA rev $28.8M (+37% QoQ); narsoplimab PDUFA Oct 17

  OMIDRIA revenue $28.8M in Q2 2021, up 37% from Q1 $21.1M; net loss narrowed to $28.6M ($0.46/sh) from $35.1M.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.95 · Median 0.75 · Most common event earnings

16 positive 6 negative 28 neutral

source · OMER on sec.gov